• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Gilead Sciences

coronavirus Omicron
Posted inCOVID-19, Infections, Research

Omicron Treatment: Most Effective Drugs

August 31, 2022September 8, 2022

Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.

Hepcludex: Effective Treatment for Chronic Hepatitis D
Posted inClinical Trials, Infections, New Drugs, Regulatory

Hepcludex: Effective Treatment for Chronic Hepatitis D

July 18, 2022September 8, 2022

Bulevirtide is the only approved antiviral drug against hepatitis delta.

Monkeypox 2022. Full Review
Posted inInfections, Research

Monkeypox 2022. Full Review

June 1, 2022September 12, 2022

Monkeypox as a new threat to humanity.

Apretude: New Drug to Prevent HIV Infection
Posted inInfections, New Drugs, Regulatory

Apretude: New Drug to Prevent HIV Infection

December 21, 2021September 8, 2022

Injecting cabotegravir once every two months will high effectively protect against HIV infection.

HIV.
Posted inInfections, Pharma & Biotech

HIV Treatment: One Pill Once a Week

April 3, 2021September 8, 2022

Lenacapavir plus islatravir is a new level of highly active antiretroviral therapy for human immunodeficiency virus infection. Gilead Sciences and Merck & Co. continue their in-depth scientific research.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News